Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase

Journal of Medicinal Chemistry

Volumn 46, Issue 15, 2003, Pages 3412-3423

  Evans, Gary B ^a   Furneaux, Richard H ^a   Lewandowicz, Andrzej ^b   Schramm, Vern L ^b   Tyler, Peter C ^a  

^a CALLAGHAN INNOVATION   (New Zealand)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBENE; DEAZAPURINE; IMMUCILLIN G; IMMUCILLIN H; NUCLEOSIDE DERIVATIVE; PURINE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; X RAY CRYSTALLOGRAPHY;

ANIMALS; CATTLE; ENZYME INHIBITORS; HUMANS; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINONES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037817418     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030145r     Document Type: Article

References (30)

1. Montgomery, J. A. Purine Nucleoside Phosphorylase: A target for drug design. Med. Res. Rev. 1993, 13, 209-228.
2. Sircar, J. C.; Gilbertsen, R. B. Purine nucleoside phosphorylase (PNP) inhibitors: Potentially selective immunosuppressive agents. Drugs Future 1988, 13, 653-668.
3. Morris, P. E., Jr.; Omura, G. A. Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis. Curr. Pharm. Design 2000, 6, 943-959.
4. Gilbertsen, R. B.; Sircar, J. C. Enzyme cascades: purine metabolism and immunosuppression. In Comprehensive Medicinal Chemistry; Hansch, C., Ed.; Pergamon Press: New York, 1990; pp 443-480.
5. Stoeckler, J. D. Purine nucleoside phosphorylase: A target for chemotherapy. In Developments in Cancer Chemotherapy; Glazer, R. I., Ed.; CRC Press: Boca Raton, FL, 1984; Vol. 1, pp 35-60.
6. Kline, P. C.; Schramm, V. L. Purine nucleoside phosphorylase. Inosine hydrolysis, tight binding of the hypoxanthine intermediate, and third-the-sites reactivity. Biochemistry 1992, 31, 5964-5973.
7. Kline, P. C.; Schramm, V. L. Purine Nucleoside Phosphorylase. Catalytic mechanism and transition state analysis of the arsenolysis reaction. Biochemistry 1993, 32, 13212-13219.
8. Kline, P. C.; Schramm, V. L. Pre-steady-state transition state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase. Biochemistry 1995, 34, 1153-1162.
9. Furneaux, R. H.; Limberg, G.; Tyler, P. C.; Schramm, V. L. Synthesis of transition state inhibitors for N-riboside hydrolases and transferases. Tetrahedron 1997, 53, 2915-2930.
10. Evans, G. B.; Furneaux, R. H.; Gainsford, G. J.; Schramm, V. L.; Tyler, P. C. Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases. Tetrahedron 2000, 56, 3053-3062.
11. Evans, G. B.; Furneaux, R. H.; Hutchinson, T. L.; Kezar, H. S.; Morris, P. E. Jr.; Schramm, V. L.; Tyler, P. C. Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: Convergent synthesis of the aza-C-nucleoside immucillins. J. Org. Chem. 2001, 66, 5723-5730.
12. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. One-third-the-sites transition state inhibitors for purine nucleoside phosphorylase. Biochemistry 1998, 37, 8615-8621.
13. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. Purine nucleoside phosphorylase. Transition state structure, transition state inhibitors and one-third-the-sites reactivity. In Enzyme Mechanisms; Frey, P. A., Northrop, D. B., Eds.; IOS Press: Washington, DC, 1999; pp 32-47.
14. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Kim, K.; Schramm, V. L. Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum. J. Biol. Chem. 2002, 277, 3219-3225.
15. Basso, L. A.; Santos, D. S.; Shi, W.; Furneaux, R. H.; Tyler, P. C.; Schramm, V. L.; Blanchard, J. S. Purine nucleoside phosphorylase from Mycobacterium tuberculosis. Analysis of inhibition by a transition state analogue and dissection by parts. Biochemistry 2001, 40, 8196-8203.
16. Kicska, G. A.; Long, L.; Hörig, H.; Fairchild, C.; Tyler, P. C.; Furneaux, R. H.; Schramm, V. L.; Kaufman, H. L. Immucillin-H selectively inhibits human T-lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4593-4598.
17. Bantia, S.; Miller, P. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Kilpatrick, J. M.; Morris, P. E.; Hutchison, T. L.; Montgomery, J. A.; Sandhu, J. S. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel potent and orally active immunosuppressive agent. Int. Immunopharmacol. 2001, 1, 1199-1210.
18. Bantia, S.; Miller, P. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Babu, Y. S.; Sandhu, J. S. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777. Int. Immunopharmacol. 2002, 2, 913-923.
19. Kicska, G. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Shi, W.; Fedorov, A.; Lewandowicz, A.; Cahill, S. M.; Almo, S. C.; Schramm, V. L. Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase. Biochemistry 2002, 41, 14489-14498.
20. Fedorov, A.; Shi, W.; Kicska, G.; Fedorov, E.; Tyler, P. C.; Furneaux, R. H.; Hanson, J. C.; Gainsford, G. J.; Larese, J. Z.; Schramm, V. L.; Almo, S. C. Transition state structure ofpurine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis. Biochemistry 2001, 40, 853-860.
21. Shi, W.; Basso, L. A.; Santos, D. S.; Tyler, P. C.; Furneaux, R. H.; Blanchard, J. C.; Almo, S. C.; Schramm, V. L. Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with Immucillin-H and its pieces. Biochemistry 2001, 40, 8204-8215.
22. David, S.; Hanessian, S. Regioselective manipulation of hydroxyl groups via organotin derivatives. Tetrahedron 1985, 41, 643-663.
23. Fleet, G. W. J.; Son, J. C. Polyhydroxylated pyrrolidines from sugar lactones: synthesis of 1,4-dideoxy-1,4-imino-D-glucitol from D-galactonolactone and synthesis of 1,4-dideoxy-1,4-imino-D-allitol, 1,4-dideoxy-1,4-imino-D-ribitol, and (2S,3R,4S)-3,4-dihydroxyproline from D-gulonolactone. Tetrahedron 1988, 44, 2637-2647.
24. Horenstein, B. A.; Zabinski, R. F.; Schramm, V. L. A new class of C-nucleoside analogues. 1-(S)-Aryl-1,4-dideoxy-1,4-imino-D-ribitols, transition state analogue inhibitors of nucleoside hydrolase. Tetrahedron Lett. 1993, 34, 7213-7216.
25. Laïb, T.; Chastanet, J.; Zhu, J. Diastereoselective synthesis of γ-hydroxy-β-amino alcohols and (2S,3S)-β-hydroxyleucine from chiral D-(N,N-dibenzylamino)serine (TBDMS) aldehyde. J. Org. Chem. 1998, 63, 1709-1713.
26. Reetz, M. T. Synthesis and diastereoselective reactions of N,N-dibenzylamino aldehydes and related compounds. Chem. Rev. 1999, 99, 1121-1162.
27. Braun, M.; Vonderhagen, A.; Waldmüller, D. Enantioselective Reformatsky reaction of methyl bromodifluoroacetate. Liebigs Ann. 1995, 1447-1450.
28. Kumamoto, H.; Tanaka, H.; Tsukioka, R.; Ishida, Y.; Nakamura, A.; Kimura, S.; Hayakawa, H.; Kato, K.; Miyasaka, T. First evident generation of purin-2-yllithium: lithiation of an 8-silyl-protected 6-chloropurine riboside as a key step for the synthesis of 2-carbon-substituted adenosines. J. Org. Chem. 1999, 64, 7773-7780.
29. Furneaux, R. H.; Tyler, P. C. Improved syntheses of 3H,5H-pyrrolo[3,2-d]pyrimidines. J. Org. Chem. 1999, 64, 8411-8412.
30. Evans, G. B.; Furneaux, R. H.; Gainsford, G. J.; Hanson, J. C.; Kicska, G. A.; Sauve, A. A.; Schramm, V. L.; Tyler, P. C. 8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases. J. Med. Chem. 2003, 46, 155-160.